Kiora Pharmaceuticals (KPRX) FCF Margin (2016 - 2024)
Kiora Pharmaceuticals' (KPRX) quarterly FCF Margin came in at 85.16% in Q1 2024, up 100.6% on a QoQ basis from 14175.86% in Q4 2020.
Kiora Pharmaceuticals (KPRX) FCF Margin (2016 - 2024) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 6 years of FCF Margin data on file, last reported at 85.16% in Q1 2024.
- Quarterly FCF Margin changed N/A year-over-year to 85.16% in Q1 2024, while the trailing twelve-month figure through Dec 2024 was 53.78% (changed N/A YoY) and the FY2024 annual result came in at 53.46%, changed N/A from the prior year.
- FCF Margin advanced to 85.16% in Q1 2024, from 14175.86% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 85.16% in Q1 2024 to a low of 14175.86% in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -18,667.20% |
| Mar 31, 2024 | 85.16% |
| Dec 31, 2020 | -14,175.86% |
| Mar 31, 2019 | -79.92% |
| Sep 30, 2018 | -884.34% |
| Jun 30, 2018 | -803.69% |
| Mar 31, 2018 | -375.43% |
| Sep 30, 2017 | -3,371.09% |
| Jun 30, 2017 | -1,671.43% |
| Mar 31, 2017 | -10.08% |
| Dec 31, 2016 | -1,272.46% |
| Sep 30, 2016 | -850.56% |
| Jun 30, 2016 | -1,140.26% |